SCHEMBL6868451

SCHEMBL6868451

NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(=O)O)NC(=O)CCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.61
MMP8 P22894 6/20 0.61
MMP12 P39900 5/20 0.61
MMP13 P45452 4/20 0.61
MMP3 P08254 3/20 0.56
MMP10 P09238 3/20 0.56
MMP9 P14780 3/20 0.56
MMP14 P50281 1/20 0.56
MME P08473 1/20 0.51
GRIA1 P42261 1/20 0.51
CTSL P07711 1/20 0.49
NAALAD2 Q9Y3Q0 1/20 0.49
NPY4R P50391 2/20 0.49
NPY1R P25929 1/20 0.49
NPY2R P49146 1/20 0.49
NPY5R Q15761 1/20 0.49
HPGDS O60760 1/20 0.48
FFAR1 O14842 1/20 0.48
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6869093 1.00 MMP2 (0.61) MMP2MMP8MMP12MMP13MMP3
SCHEMBL14122651 1.00 MMP2 (0.61) MMP2MMP8MMP12MMP13MMP3
SCHEMBL14122959 1.00 MMP2 (0.61) MMP2MMP8MMP12MMP13MMP3
SCHEMBL6868740 0.96 MMP2 (0.64) MMP2MMP8MMP12MMP13MMP3
SCHEMBL19112074 0.96 MMP2 (0.64) MMP2MMP8MMP12MMP13MMP3
SCHEMBL14122653 0.96 MMP2 (0.64) MMP2MMP8MMP12MMP13MMP3
SCHEMBL6869529 0.90 MMP12 (0.72) MMP2MMP8MMP12MMP13MMP3
SCHEMBL19111742 0.90 MMP12 (0.72) MMP2MMP8MMP12MMP13MMP3
SCHEMBL6868541 0.90 MMP12 (0.72) MMP2MMP8MMP12MMP13MMP3
SCHEMBL14122841 0.90 MMP12 (0.72) MMP2MMP8MMP12MMP13MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470514-B1 PSEUDO-DIPEPTIDES AS MMP INHIBITORS COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2017-07-12 EP disclosed
US-20120309674-A1 PSEUDODIPEPTIDES AS MMP INHIBITORS COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT (FR) 2012-12-06 US disclosed
US-20120309674-A1 PSEUDODIPEPTIDES AS MMP INHIBITORS COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT (FR) 2012-12-06 US disclosed
WO-2011023864-A1 PSEUDODIPEPTIDES AS MMP INHIBITORS COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309674-A1 PSEUDODIPEPTIDES AS MMP INHIBITORS MMP3, MMP11, TIMP3 MMP2 16/4885MMP8 40/4885MMP12 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.